Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
07 mars 2018 07h30 HE
|
Esperion Therapeutics, Inc.
— Study 4 Met Primary Endpoint with 28% Additional LDL-C Lowering on Background Ezetimibe and Up to the Lowest Daily Dose of a Statin — — hsCRP Reduction of 33% — — Observed to be Safe and...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
23 févr. 2018 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results
20 févr. 2018 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 16h30 HE
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Wednesday, January 10, 2018 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time ANN ARBOR, Mich., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc....
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
14 déc. 2017 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
19 mai 2017 16h30 HE
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Tuesday, May 23, 2017 at 9:00 a.m. Eastern Time ANN ARBOR, Mich., May 19, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18 mai 2017 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 18, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
04 mai 2017 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference
28 mars 2017 16h30 HE
|
Esperion Therapeutics, Inc.
Fireside Chat on Tuesday, April 4, 2017 at 1:40 p.m. Eastern Time ANN ARBOR, Mich., March 28, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company...
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
07 mars 2017 08h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary,...